mMTORC1 activation in childhood ependymoma and response to sirolimus

Daniel C. Bowers, Blanka Kucejova, Linda Margraf, Lynn Gargan, James Brugarolas

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient's tumor.

Original languageEnglish (US)
Pages (from-to)797-801
Number of pages5
JournalJournal of Neuro-Oncology
Issue number3
StatePublished - Jul 1 2011


  • Ependymoma
  • Rapamycin
  • Sirolimus
  • mTORC1

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'mMTORC1 activation in childhood ependymoma and response to sirolimus'. Together they form a unique fingerprint.

Cite this